{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:02:57Z","timestamp":1793278977561,"version":"4.5.0"},"reference-count":70,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Older adults with cancer are surviving longer due to earlier detection and more effective treatments for advanced stages. This population is at an elevated risk of osteoporosis due to age-related changes in bone density as well as the impact of cancer and cancer treatments on the skeletal system. Main Body: Cancer treatments are associated with increased bone loss and fracture risk via a variety of mechanisms. International guidelines recommend screening for cancer treatment-induced bone loss and provide treatment algorithms for pharmacological agents for those on hormonal therapy. There is a paucity of guidelines on bone health protection for those receiving intermittent glucocorticoid and newer immunotherapy regimes. Results: All patients receiving cancer treatment should undergo an individualised fracture risk assessment to optimise their bone health with regular review and reassessment of their risk profile. Dedicated bone health guidelines in cancer populations should be expanded to consider the impact of newer treatment modalities. All patients should receive education around non-pharmacological management and undergo a shared decision-making approach where there are indications for bone-targeted agents. Conclusions: Bone health assessment is an integral part of comprehensive geriatric assessment for older people with cancer. Strategies to minimise bone density loss and reduce fracture risk are an important consideration for cancer survivorship programmes for the majority of people and require a standardised approach.<\/jats:p>","DOI":"10.3390\/cancers17172878","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:39:01Z","timestamp":1756744741000},"page":"2878","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Management of Bone Health Considerations in Patients with Cancer"],"prefix":"10.3390","volume":"17","author":[{"given":"Michelle","family":"Brennan","sequence":"first","affiliation":[{"name":"Department of Geriatric Medicine, University Hospital Limerick, V94 F858 Limerick, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Kalsi","sequence":"additional","affiliation":[{"name":"Department of Ageing and Health, Geriatric Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London SE1 9RT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/bjc.2012.366","article-title":"Projections of cancer prevalence in the United Kingdom, 2010\u20132040","volume":"107","author":"Maddams","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_2","unstructured":"Harker, R. (2025, August 01). Cancer Statistics for England. December 2024. Available online: https:\/\/researchbriefings.files.parliament.uk\/documents\/SN06887\/SN06887.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.21.00138","article-title":"Immunotherapy in older adults with cancer","volume":"39","author":"Presley","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_4","unstructured":"NHS (2024, May 01). Adult Survivorship from Concept to Innovation. National Cancer Survivorship Initiative, Available online: www.improvement.nhs.uk\/cancer\/survivorship."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","article-title":"SCOPE 2021: A new scorecard for osteoporosis in Europe","volume":"16","author":"Kanis","year":"2021","journal-title":"Arch. Osteoporos."},{"key":"ref_8","unstructured":"Cancer Research UK (2024, May 01). Cancer Mortality for Common Cancers. Available online: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/mortality\/common-cancers-compared."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2666-7568(23)00285-4","article-title":"Risk of fractures in half a million survivors of 20 cancers: A population-based matched cohort study using linked English electronic health records","volume":"5","author":"Buzasi","year":"2024","journal-title":"Lancet Healthy Longev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11914-013-0154-3","article-title":"Osteoporosis and cancer","volume":"11","author":"Drake","year":"2013","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101782","DOI":"10.1016\/j.beem.2023.101782","article-title":"Bone health and menopause: Osteoporosis prevention and treatment","volume":"38","year":"2024","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1759720X11430858","article-title":"Aging and bone loss: New insights for the clinician","volume":"4","author":"Demontiero","year":"2012","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/ageing\/afx201","article-title":"Projections of multi-morbidity in the older population in England to 2035: Estimates from the Population Ageing and Care Simulation (PACSim) model","volume":"47","author":"Kingston","year":"2018","journal-title":"Age Ageing"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/jbmr.3381","article-title":"The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: Economic evaluation of the SCOOP study","volume":"33","author":"Turner","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00198-011-1724-9","article-title":"Prevalence of osteoporosis among cancer patients in Germany: Prospective data from an oncological rehabilitation clinic","volume":"23","author":"Hartmann","year":"2012","journal-title":"Osteoporos. Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.01696","article-title":"Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline","volume":"37","author":"Shapiro","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrendo.2013.179","article-title":"The role of estrogen and androgen receptors in bone health and disease","volume":"9","author":"Manolagas","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1007\/s00198-017-4189-7","article-title":"Inflammatory diseases and bone fragility","volume":"28","author":"Briot","year":"2017","journal-title":"Osteoporos. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e40476","DOI":"10.1097\/MD.0000000000040476","article-title":"Osteosarcopenia in patients with cancer: A systematic review and meta-analysis","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Confavreux, C.B., Follet, H., Mitton, D., Pialat, J.B., and Clezardin, P. (2021). Fracture risk evaluation of bone metastases: A burning issue. Cancers, 13.","DOI":"10.3390\/cancers13225711"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11864-021-00835-2","article-title":"Cancer treatment\u2013induced bone loss (CTIBL): State of the art and proper Management in Breast Cancer Patients on endocrine therapy","volume":"22","author":"Diana","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_23","first-page":"1029","article-title":"Aromatase inhibitors and bone loss","volume":"20","author":"Perez","year":"2006","journal-title":"Oncology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.ejca.2009.09.026","article-title":"The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer","volume":"45","author":"Hadji","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/2051415816654048","article-title":"The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer","volume":"9","author":"Gunner","year":"2016","journal-title":"J. Clin. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.euo.2024.01.016","article-title":"Risk of fractures and falls in men with advanced or metastatic prostate cancer receiving androgen deprivation therapy and treated with novel androgen receptor signalling inhibitors: A systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Jones","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5534\/wjmh.210061","article-title":"Multidisciplinary consensus on the prevention and treatment of osteoporosis and fragility fractures in patients with prostate cancer receiving androgen-deprivation therapy","volume":"40","author":"Casado","year":"2022","journal-title":"World J. Men\u2019s Health"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","article-title":"Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody","volume":"76","author":"Costa","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","article-title":"NCCN task force report: Bone health in cancer care","volume":"11","author":"Gralow","year":"2013","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_32","first-page":"6957","article-title":"Effect of cytotoxic chemotherapy on bone health among breast cancer patients. Does it require intervention?","volume":"29","author":"Nisha","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11657-023-01231-z","article-title":"Cytotoxic chemotherapy is associated with decreased bone mineral density in postmenopausal women with early and locally advanced breast cancer","volume":"18","author":"Nisha","year":"2023","journal-title":"Arch. Osteoporos."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2012.02.008","article-title":"Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?","volume":"38","author":"Hadji","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/jbmr.2415","article-title":"Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss","volume":"30","author":"Quach","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100205","DOI":"10.1016\/j.jbo.2018.10.004","article-title":"Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management","volume":"15","author":"Coleman","year":"2019","journal-title":"J. Bone Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3109\/0284186X.2015.1062139","article-title":"The need for radiotherapy in Europe in 2020: Not only data but also a cancer plan","volume":"54","author":"Borras","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11914-015-0266-z","article-title":"Chemotherapy-and irradiation-induced bone loss in adults with solid tumors","volume":"13","author":"Wissing","year":"2015","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_39","first-page":"e220328","article-title":"Radiotherapy-related insufficiency fractures and bone mineral density: What is the connection?","volume":"12","author":"Barraclough","year":"2023","journal-title":"Endocr. Connect."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ijrobp.2019.09.012","article-title":"Pelvic insufficiency fractures after external beam radiation therapy for gynecologic cancers: A meta-analysis and meta-regression of 3929 patients","volume":"106","author":"Sapienza","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/cncr.32807","article-title":"Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women","volume":"126","author":"Salcedo","year":"2020","journal-title":"Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1590\/1806-9282.65.6.902","article-title":"Pathological fracture after radiotherapy: Systematic review of literature","volume":"65","author":"Soares","year":"2019","journal-title":"Rev. Da Assoc. M\u00e9dica Bras."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Nguy\u1ec5n, M.V., Carlier, C., Nich, C., Gouin, F., and Crenn, V. (2021). Fracture risk of long bone metastases: A review of current and new decision-making tools for prophylactic surgery. Cancers, 13.","DOI":"10.3390\/cancers13153662"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e056600","DOI":"10.1136\/bmjopen-2021-056600","article-title":"RadBone: Bone toxicity following pelvic radiotherapy\u2013a prospective randomised controlled feasibility study evaluating a musculoskeletal health package in women with gynaecological cancers undergoing pelvic radiotherapy","volume":"12","author":"Grigoriadou","year":"2022","journal-title":"BMJ Open"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bone.2009.09.002","article-title":"Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations","volume":"46","author":"Willey","year":"2010","journal-title":"Bone"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bone.2014.06.030","article-title":"PTH1\u201334 alleviates radiotherapy-induced local bone loss by improving osteoblast and osteocyte survival","volume":"67","author":"Chandra","year":"2014","journal-title":"Bone"},{"key":"ref_47","first-page":"1681","article-title":"Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies","volume":"8","author":"Greenstein","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.steroids.2016.02.019","article-title":"New dimension of glucocorticoids in cancer treatment","volume":"111","author":"Lin","year":"2016","journal-title":"Steroids"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","article-title":"Glucocorticoid-induced osteoporosis: An update","volume":"61","author":"Compston","year":"2018","journal-title":"Endocrine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00223-012-9630-5","article-title":"Management of glucocorticoid-induced osteoporosis","volume":"91","author":"Rizzoli","year":"2012","journal-title":"Calcif. Tissue Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"17","author":"Gregson","year":"2022","journal-title":"Arch. Osteoporos."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.15735","article-title":"The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocytopenia receiving steroids: A British Society for Haematology Good Practice Paper","volume":"185","author":"Hill","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/art.22294","article-title":"Fracture risk with intermittent high-dose oral glucocorticoid therapy","volume":"56","author":"Bracke","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s00198-017-4115-z","article-title":"Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis","volume":"28","author":"Oshagbemi","year":"2017","journal-title":"Osteoporos. Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/EDBK_201435","article-title":"Immunotherapy in older adults with advanced cancers: Implications for clinical decision-making and future research","volume":"38","author":"Kanesvaran","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","article-title":"Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: A seminal case series","volume":"6","author":"Moseley","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ijc.33592","article-title":"Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis","volume":"149","author":"Filippini","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/JIPO.JIPO_12_19","article-title":"Rheumatic and musculoskeletal adverse events with immune checkpoint inhibitors: Data from the United States Food and Drug Administration adverse event reporting system","volume":"2","author":"Pundole","year":"2019","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Liu, H., Li, Y., Li, J., Zhang, Q., Wu, J., Li, X., Meng, L., Cao, S., and Li, H. (2023). Musculoskeletal adverse events induced by immune checkpoint inhibitors: A large-scale pharmacovigilance study. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1199031"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00198-023-06690-1","article-title":"Fracture rate increases after immune checkpoint inhibitor treatment: A potential new immune related adverse event","volume":"34","author":"Ye","year":"2023","journal-title":"Osteoporos. Int."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"20420188231157194","DOI":"10.1177\/20420188231157194","article-title":"Immune checkpoint inhibitors: Friend or foe for osteoporosis","volume":"14","author":"Tang","year":"2023","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Peraza-Delgado, A., S\u00e1nchez-G\u00f3mez, M.B., G\u00f3mez-Salgado, J., Romero-Mart\u00edn, M., Novo-Mu\u00f1oz, M., and Duarte-Cl\u00edments, G. (2020). Non-pharmacological interventions towards preventing the triad osteoporosis-falls risk-hip fracture, in population older than 65. Scoping Review. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082329"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/scd.12877","article-title":"Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis","volume":"44","author":"Zhang","year":"2024","journal-title":"Spec. Care Dent."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_65","first-page":"547","article-title":"Romosozumab for the treatment of osteoporosis\u2013a systematic review","volume":"48","author":"McClung","year":"2025","journal-title":"J. Endocrinol. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jgo.2018.08.006","article-title":"The assessment, management, and reporting of falls, and the impact of falls on cancer treatment in community-dwelling older patients receiving cancer treatment: Results from a mixed-methods study","volume":"10","author":"Sattar","year":"2019","journal-title":"J. Geriatr. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clon.2020.03.011","article-title":"Falls and cancer","volume":"32","author":"Morris","year":"2020","journal-title":"Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamainternmed.2015.0747","article-title":"Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: A randomized clinical trial","volume":"175","author":"Greenspan","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"c5146","DOI":"10.1136\/bmj.c5146","article-title":"Implementing shared decision making in the NHS","volume":"341","author":"Elwyn","year":"2010","journal-title":"BMJ"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.pec.2015.12.014","article-title":"Expert and patient consensus on a dynamic model for shared decision-making in frail older patients","volume":"99","author":"Fluit","year":"2016","journal-title":"Patient Educ. Couns."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2878\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:37:26Z","timestamp":1760035046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":70,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17172878"],"URL":"https:\/\/doi.org\/10.3390\/cancers17172878","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}